Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.4.22.32 (bromelain)
 1,025 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The ascites form of a chemically induced guinea pig hepatoma, line-10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement. Pretreatment of line-10 cells with certain proteolytic enzymes rendered tham susceptible to the killing action of antibody and guinea pig complement. The effects of enzyme pretreatment were dependent on enzyme concentration, temperature, and could be blocked by addition of competitive or non-competitive inhibitors. The effect of the enzyme treatment could reversed by incubating the treated cells at 37 degrees C (but not at 0 degrees C), in the absence of the enzyme. Effective enzymes included ficin, bromelain, pronase, elastase, papain, trypsin, collagenase, lipases type I and type VI, and the neuraminidase preparation isolated from Clostridium perfringens. The activity of the lipase preparations and the neuraminidase preparation isolated from Clostridium perfringens appeared to be caused by proteolytic enzyme contamination. Enzyme preparations that proved ineffecitve in rendering the line-10 cells sensitive to killing by antibody and guinea pig complement included DNase, RNase, beta-glucuronidase type 6A or type B10, hyaluronidase type V or type VI, and pectinesterase.
 ...
PMID:Lysis of tumor cells by antibody and complement. VI. Enhanced killing of enzyme-pretreated tumor cells. 17 70

Treatment of lymphocytic choriomeningitis virus with proteolytic enzymes, hyaluronidase, and phospholipase C increased infectious titres. Biochemical analysis of bromelain- and trypsin-treated virus revealed that infectivity was high in spite of the decrease to low or undetectable levels of all viral glycoproteins as well as partial degradation of the nucleoprotein.
 ...
PMID:Lymphocytic choriomeningitis virus. VII. Structural alterations of the virion by treatment with proteolytic enzymes without loss of infectivity. 637 2

About 30-40% of patients with insect venom allergy have IgE antibodies reacting with both honeybee and Vespula venom. Apart from true double sensitization, IgE against cross-reactive carbohydrate determinants (CCDs, alpha1,3-fucosylated N-glycans) with low clinical relevance is the most frequent and often only cause for the multiple reactivity. Venom hyaluronidases have been identified as the most important allergens displaying CCDs, whereas cross-reactions through the hyaluronidases' peptide backbones are less common. If IgE binding to CCDs is disregarded, Vespula venom hyaluronidase is only a minor allergen. In-vitro tests using fucosylated plant glycoproteins (e.g. assessment of specific IgE antibodies by CAP-FEiA to bromelain) are helpful in identifying sera containing CCD-specific IgE, although a positive result (occurring in 70-80% of all double-positive sera) does not reliably exclude true double-sensitization. Reciprocal in-vitro inhibition including non-venom inhibitor proteins rich in CCDs is the method of choice to discriminate between double-sensitization and cross-reactivity. Future in-vitro diagnosis will be markedly improved when recombinant allergens lacking CCDs become commercially available.
 ...
PMID:[Cross-reactivity to honeybee and wasp venom]. 1826 54